08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

CytImmune, AstraZeneca deal

AstraZeneca partnered with CytImmune to evaluate the feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune said the companies plan to conduct preclinical testing throughout 2013 before deciding...
00:48 , Dec 28, 2012 |  BC Extra  |  Company News

AZN, CytImmune in cancer deal

AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered with CytImmune Sciences Inc. (Rockville, Md.) to evaluate the feasibility of combining an undisclosed preclinical cancer compound from the pharma with CytImmune's CYT-6091 . CytImmune said the companies plan to...
08:00 , Feb 4, 2010 |  BC Innovations  |  Tools & Techniques

Nanoparticle drug delivery heats up

Although there is broad consensus on the properties of a good therapeutic nanoparticle-the ability to concentrate a drug and release it slowly at a specific site-achieving such targeted delivery has remained elusive. Now, a pair...
08:00 , Nov 13, 2008 |  BC Innovations  |  Cover Story

Prostate-bound nanoparticles

Platinum drugs such as cisplatin, which have been successfully used for the treatment of different types of cancer, are notoriously inefficient with prostate cancer, due mostly to the particular physiology of the prostate and the...
08:00 , Feb 21, 2008 |  BC Innovations  |  Tools & Techniques

Serial killing nanocarriers

Among the challenges facing researchers in designing tumor-targeted drug delivery systems are choosing a ligand that selectively targets the tumor and consistently delivering therapeutic payload to all parts of the tumor. A group at the...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Clinical News

CYT-6091: Preliminary Phase I data

In an open-label, dose-escalation, U.S. Phase I trial there was about a 10-fold increase in the number of gold nanoparticles in tumors from 5 of 6 patients compared with adjacent healthy tissue. There were no...
07:00 , Jun 5, 2006 |  BC Week In Review  |  Clinical News

CYT-6091: Phase I started

CytImmune began an open-label, dose-escalation, U.S. Phase I trial in up to 42 patients. CytImmune Sciences Inc. , Rockville, Md.   Product: CYT-6091   Business: Cancer   Molecular target: NA   Description: TNF-bearing pegylated colloidal...